Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
- Ruperto, Nicolino
- Brunner, Hermine I
- Quartier, Pierre
- Constantin, Tamás
- Wulffraat, Nico
- Horneff, Gerd
- Brik, Riva
- McCann, Liza
- Kasapcopur, Ozgur
- Rutkowska-Sak, Lidia
- Schneider, Rayfel
- Berkun, Yackov
- Calvo, Inmaculada
- Erguven, Muferet
- Goffin, Laurence
- Hofer, Michael
- Kallinich, Tilmann
- Oliveira, Sheila K
- Uziel, Yosef
- Viola, Stefania
- Nistala, Kiran
- Wouters, Carine
- Cimaz, Rolando
- Ferrandiz, Manuel A
- Flato, Berit
- Gamir, Maria Luz
- Kone-Paut, Isabelle
- Grom, Alexei
- Magnusson, Bo
- Ozen, Seza
- Sztajnbok, Flavio
- Lheritier, Karine
- Abrams, Ken
- Kim, Dennis
- Martini, Alberto
- Lovell, Daniel J
- PRINTO
- PRCSG
Publication date
December 2012
DOI Publisher
Massachusetts Medical Society Journal
New England Journal of MedicineAbstract
Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials.status: publishe
Add to ORKG